|
US4078060A
(en)
*
|
1976-05-10 |
1978-03-07 |
Richardson-Merrell Inc. |
Method of inducing an estrogenic response
|
|
US4434228A
(en)
*
|
1982-04-20 |
1984-02-28 |
Genex Corporation |
Immobilization of biological materials in condensed polyalkyleneimine polymers
|
|
US4816568A
(en)
*
|
1986-05-16 |
1989-03-28 |
International Minerals & Chemical Corp. |
Stabilization of growth hormones
|
|
JPS63287730A
(ja)
|
1987-05-20 |
1988-11-24 |
Nippon Shokubai Kagaku Kogyo Co Ltd |
経皮吸収促進剤およびこれを含有してなる皮膚外用剤
|
|
US5420105A
(en)
*
|
1988-09-23 |
1995-05-30 |
Gustavson; Linda M. |
Polymeric carriers for non-covalent drug conjugation
|
|
US5252713A
(en)
*
|
1988-09-23 |
1993-10-12 |
Neorx Corporation |
Polymeric carriers for non-covalent drug conjugation
|
|
US5744166A
(en)
*
|
1989-02-25 |
1998-04-28 |
Danbiosyst Uk Limited |
Drug delivery compositions
|
|
US6126945A
(en)
*
|
1989-10-03 |
2000-10-03 |
Pharmacia Ab |
Tumor killing effects of enterotoxins, superantigens, and related compounds
|
|
US5674980A
(en)
*
|
1989-12-21 |
1997-10-07 |
Biogen Inc |
Fusion protein comprising tat-derived transport moiety
|
|
US5804604A
(en)
|
1989-12-21 |
1998-09-08 |
Biogen, Inc. |
Tat-derived transport polypeptides and fusion proteins
|
|
US5629020A
(en)
*
|
1994-04-22 |
1997-05-13 |
Emisphere Technologies, Inc. |
Modified amino acids for drug delivery
|
|
ES2095959T3
(es)
|
1990-10-24 |
1997-03-01 |
Allelix Biopharma |
Inhibidores de la replicacion del virus vih a base de peptidos.
|
|
GB9120306D0
(en)
*
|
1991-09-24 |
1991-11-06 |
Graham Herbert K |
Method and compositions for the treatment of cerebral palsy
|
|
US5607691A
(en)
*
|
1992-06-12 |
1997-03-04 |
Affymax Technologies N.V. |
Compositions and methods for enhanced drug delivery
|
|
JP2702285B2
(ja)
|
1992-08-21 |
1998-01-21 |
バイオジェン，インコーポレイテッド |
Ｔａｔ由来の輸送ポリペプチド
|
|
US5260082A
(en)
|
1992-09-16 |
1993-11-09 |
Kraft General Foods, Inc. |
Baked goods, doughs or batters, dry mixes and methods for producing thereof
|
|
US5877278A
(en)
*
|
1992-09-24 |
1999-03-02 |
Chiron Corporation |
Synthesis of N-substituted oligomers
|
|
US5709861A
(en)
*
|
1993-04-22 |
1998-01-20 |
Emisphere Technologies, Inc. |
Compositions for the delivery of antigens
|
|
US6986893B2
(en)
*
|
1993-12-28 |
2006-01-17 |
Allergan, Inc. |
Method for treating a mucus secretion
|
|
EP1602379A1
(en)
|
1993-12-28 |
2005-12-07 |
Allergan, Inc. |
Botulinum toxin B for treating spastic muscle
|
|
US6974578B1
(en)
*
|
1993-12-28 |
2005-12-13 |
Allergan, Inc. |
Method for treating secretions and glands using botulinum toxin
|
|
US5766605A
(en)
*
|
1994-04-15 |
1998-06-16 |
Mount Sinai School Of Medicine Of The City University Of New York |
Treatment of autonomic nerve dysfunction with botulinum toxin
|
|
DE69526340T2
(de)
*
|
1994-05-09 |
2002-11-14 |
William J. Binder |
Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN
|
|
NO180167C
(no)
*
|
1994-09-08 |
1997-02-26 |
Photocure As |
Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
|
|
US6232295B1
(en)
|
1994-10-12 |
2001-05-15 |
Jon Faiz Kayyem |
Cell-specific contrast agent and gene delivery vehicles
|
|
US5512547A
(en)
*
|
1994-10-13 |
1996-04-30 |
Wisconsin Alumni Research Foundation |
Pharmaceutical composition of botulinum neurotoxin and method of preparation
|
|
US5756468A
(en)
*
|
1994-10-13 |
1998-05-26 |
Wisconsin Alumni Research Foundation |
Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation
|
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
|
GB9508204D0
(en)
*
|
1995-04-21 |
1995-06-07 |
Speywood Lab Ltd |
A novel agent able to modify peripheral afferent function
|
|
GB9600272D0
(en)
*
|
1996-01-06 |
1996-03-06 |
Univ Nottingham |
Polymers
|
|
JP2000509394A
(ja)
|
1996-05-01 |
2000-07-25 |
アンティバイラルズ インコーポレイテッド |
細胞膜を横切って物質を輸送するためのポリペプチド結合体
|
|
GB9623051D0
(en)
|
1996-11-06 |
1997-01-08 |
Schacht Etienne H |
Delivery of DNA to target cells in biological systems
|
|
FR2755976B1
(fr)
|
1996-11-15 |
1999-01-15 |
Idm Immuno Designed Molecules |
Nouveaux complexes d'acides nucleiques et de polymere substitue par des residus entrainant la destabilisation des membranes cellulaires
|
|
US6228161B1
(en)
*
|
1996-12-30 |
2001-05-08 |
Minerals Technologies Inc. |
Use of calcium carbonate in an acidic aqueous media
|
|
US5798587A
(en)
*
|
1997-01-22 |
1998-08-25 |
Industrial Technology Research Institute |
Cooling loop structure of high speed spindle
|
|
FR2759298B1
(fr)
|
1997-02-10 |
1999-04-09 |
Rhone Poulenc Rorer Sa |
Formulation de particules agent(s) de transfection cationique(s)/acides nucleiques stabilisees
|
|
AU734827B2
(en)
*
|
1997-05-21 |
2001-06-21 |
Board Of Trustees Of The Leland Stanford Junior University |
Composition and method for enhancing transport across biological membranes
|
|
US7150881B2
(en)
|
1997-06-26 |
2006-12-19 |
Mylan Technologies, Inc. |
Adhesive mixture for transdermal delivery of highly plasticizing drugs
|
|
EP1030927A1
(en)
|
1997-11-12 |
2000-08-30 |
Valentis Inc. |
Expression plasmids for multiepitope nucleic acid-based vaccines
|
|
US5985434A
(en)
*
|
1997-11-25 |
1999-11-16 |
Kimberly-Clark Worldwide, Inc. |
Absorbent foam
|
|
WO1999029721A1
(en)
|
1997-12-10 |
1999-06-17 |
Washington University |
Anti-pathogen system and methods of use thereof
|
|
WO1999042091A2
(en)
*
|
1998-02-19 |
1999-08-26 |
Massachusetts Institute Of Technology |
Use of polycations as endosomolytic agents
|
|
US6011646A
(en)
|
1998-02-20 |
2000-01-04 |
The Regents Of The Unviersity Of California |
Method to adjust multilayer film stress induced deformation of optics
|
|
AU3311599A
(en)
|
1998-02-25 |
1999-09-15 |
Iomai Corporation |
Use of skin penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response induced by adp-ribosylating exotoxin
|
|
RU2203058C2
(ru)
|
1998-04-27 |
2003-04-27 |
Фудзисава Фармасьютикал Ко., Лтд. |
Фармацевтическая композиция
|
|
US6261679B1
(en)
*
|
1998-05-22 |
2001-07-17 |
Kimberly-Clark Worldwide, Inc. |
Fibrous absorbent material and methods of making the same
|
|
BR9912070A
(pt)
*
|
1998-07-13 |
2001-04-10 |
Expression Genetics Inc |
Análogo de poliéster de poli-l-lisina como um solúvel, veìculo de distribuição de gene biodegradável
|
|
US6280937B1
(en)
*
|
1998-08-14 |
2001-08-28 |
Rigel Pharmaceuticals, Inc. |
Shuttle vectors
|
|
TW574036B
(en)
|
1998-09-11 |
2004-02-01 |
Elan Pharm Inc |
Stable liquid compositions of botulinum toxin
|
|
US6958147B1
(en)
|
1998-10-26 |
2005-10-25 |
Licentia Ltd |
Use of VEGF-C to prevent restenosis
|
|
BR9914891A
(pt)
|
1998-10-27 |
2001-07-17 |
Mayo Foundation |
Processos para aperfeiçoamento de cura de ferimento
|
|
CA2348823A1
(en)
|
1998-12-02 |
2000-06-08 |
I.D.M. Immuno-Designed Molecules |
New oligomeric conjugates liable to transfer biological molecules into cells
|
|
WO2000034308A2
(en)
|
1998-12-10 |
2000-06-15 |
Washington University |
Protein transduction system and methods of use thereof
|
|
US6627632B2
(en)
*
|
1998-12-14 |
2003-09-30 |
Cellegy Pharmaceuticals, Inc. |
Compositions and methods for the treatment of anorectal disorders
|
|
AU770803B2
(en)
|
1998-12-23 |
2004-03-04 |
Idea Ag |
Improved formulation for topical non-invasive application in vivo
|
|
US7056656B1
(en)
*
|
1999-01-25 |
2006-06-06 |
University Of Medicine And Dentistry Of New Jersey |
Tat-derived oligourea and its method of production and use in high affinity and specific binding HIV-1 TAR RNA
|
|
ES2160485B1
(es)
|
1999-04-23 |
2002-05-16 |
Lipotec Sa |
Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
|
|
DE19925739A1
(de)
|
1999-06-07 |
2000-12-21 |
Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh |
Therapeutikum mit einem Botulinum-Neurotoxin
|
|
US7442764B2
(en)
*
|
1999-06-07 |
2008-10-28 |
Mirns Bio Corporation |
Reversible modification of amine-containing compounds
|
|
US20030236214A1
(en)
|
1999-06-09 |
2003-12-25 |
Wolff Jon A. |
Charge reversal of polyion complexes and treatment of peripheral occlusive disease
|
|
US7008924B1
(en)
*
|
1999-07-21 |
2006-03-07 |
Amgen, Inc. |
VGF fusion polypeptides
|
|
US7229961B2
(en)
*
|
1999-08-24 |
2007-06-12 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into ocular tissues
|
|
MXPA02001857A
(es)
*
|
1999-08-24 |
2003-07-14 |
Cellgate Inc |
Composiciones y metodos para incrementar la entrega de drogas a traves y dentro de tejidos epiteliales.
|
|
US6669951B2
(en)
*
|
1999-08-24 |
2003-12-30 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into epithelial tissues
|
|
US6730293B1
(en)
*
|
1999-08-24 |
2004-05-04 |
Cellgate, Inc. |
Compositions and methods for treating inflammatory diseases of the skin
|
|
US20030104622A1
(en)
*
|
1999-09-01 |
2003-06-05 |
Robbins Paul D. |
Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
|
|
US6544548B1
(en)
*
|
1999-09-13 |
2003-04-08 |
Keraplast Technologies, Ltd. |
Keratin-based powders and hydrogel for pharmaceutical applications
|
|
US6458763B1
(en)
*
|
1999-09-17 |
2002-10-01 |
Depuy Orthopeadics |
Bone sialoprotein-based compositions for enhancing connective tissue repair
|
|
US6773928B1
(en)
|
1999-09-22 |
2004-08-10 |
The United States Of America As Represented By The Secretary Of The Army |
Compositions and methods for enhancing bioassay performance
|
|
US6610820B1
(en)
|
1999-10-12 |
2003-08-26 |
University Of Lausanne |
Cell-permeable peptide inhibitors of the JNK signal transduction pathway
|
|
US6511676B1
(en)
*
|
1999-11-05 |
2003-01-28 |
Teni Boulikas |
Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
|
|
US6844324B1
(en)
*
|
1999-11-12 |
2005-01-18 |
Massachusetts Institute Of Technology |
Modular peptide mediated intracellular delivery system and uses therefore
|
|
US7070807B2
(en)
*
|
1999-12-29 |
2006-07-04 |
Mixson A James |
Branched histidine copolymers and methods for using same
|
|
US20040109871A1
(en)
*
|
2000-01-06 |
2004-06-10 |
Pascual David W. |
M cell directed vaccines
|
|
US20030118598A1
(en)
*
|
2000-02-08 |
2003-06-26 |
Allergan, Inc. |
Clostridial toxin pharmaceutical compositions
|
|
US7780967B2
(en)
*
|
2000-02-08 |
2010-08-24 |
Allergan, Inc. |
Reduced toxicity Clostridial toxin pharmaceutical compositions
|
|
US20020009491A1
(en)
*
|
2000-02-14 |
2002-01-24 |
Rothbard Jonathan B. |
Compositions and methods for enhancing drug delivery across biological membranes and tissues
|
|
AT411041B
(de)
*
|
2000-05-18 |
2003-09-25 |
Josef Lindenberg |
Verfahren zur herstellung von glasfliesen, glasbordüren, glasdekorpaneelen oder dgl.
|
|
US6670322B2
(en)
|
2000-06-01 |
2003-12-30 |
Wisconsin Alumni Research Foundation |
Method of targeting pharmaceuticals to motor neurons
|
|
US6306423B1
(en)
*
|
2000-06-02 |
2001-10-23 |
Allergan Sales, Inc. |
Neurotoxin implant
|
|
US20040033241A1
(en)
*
|
2000-06-02 |
2004-02-19 |
Allergan, Inc. |
Controlled release botulinum toxin system
|
|
US20030215412A1
(en)
|
2000-07-21 |
2003-11-20 |
Essentia Biosystems, Inc. |
Induction of hair growth with vascular endothelial growth factor
|
|
US6903187B1
(en)
*
|
2000-07-21 |
2005-06-07 |
Allergan, Inc. |
Leucine-based motif and clostridial neurotoxins
|
|
US20040220100A1
(en)
|
2000-07-21 |
2004-11-04 |
Essentia Biosystems, Inc. |
Multi-component biological transport systems
|
|
US20030219462A1
(en)
|
2000-07-21 |
2003-11-27 |
Allergan Sales, Inc |
Clostridial neurotoxin compositions and modified clostridial neurotoxins
|
|
US7491799B2
(en)
|
2000-07-21 |
2009-02-17 |
Allergan, Inc. |
Modified botulinum neurotoxins
|
|
CA2797652C
(en)
*
|
2000-07-21 |
2016-03-08 |
Revance Therapeutics, Inc. |
Multi-component biological transport systems
|
|
US6696038B1
(en)
*
|
2000-09-14 |
2004-02-24 |
Expression Genetics, Inc. |
Cationic lipopolymer as biocompatible gene delivery agent
|
|
US6831059B2
(en)
*
|
2000-10-20 |
2004-12-14 |
Allergan, Inc. |
Compositions and methods for treating gonadotrophin related illnesses
|
|
US20020127247A1
(en)
|
2000-11-17 |
2002-09-12 |
Allergen Sales, Inc. |
Modified clostridial neurotoxins with altered biological persistence
|
|
US7255865B2
(en)
*
|
2000-12-05 |
2007-08-14 |
Allergan, Inc. |
Methods of administering botulinum toxin
|
|
US20020086036A1
(en)
*
|
2000-12-05 |
2002-07-04 |
Allergan Sales, Inc. |
Methods for treating hyperhidrosis
|
|
WO2002065986A2
(en)
|
2001-02-16 |
2002-08-29 |
Cellgate, Inc. |
Transporters comprising spaced arginine moieties
|
|
CA2367636C
(en)
*
|
2001-04-12 |
2010-05-04 |
Lisa Mckerracher |
Fusion proteins
|
|
US7226605B2
(en)
*
|
2001-07-27 |
2007-06-05 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Botulinum toxin in the treatment or prevention of acne
|
|
AU2002363523A1
(en)
*
|
2001-11-07 |
2003-05-19 |
Pharmacia Corporation |
Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
|
|
US7060498B1
(en)
*
|
2001-11-28 |
2006-06-13 |
Genta Salus Llc |
Polycationic water soluble copolymer and method for transferring polyanionic macromolecules across biological barriers
|
|
MXPA04005611A
(es)
*
|
2001-12-11 |
2005-04-19 |
Cellgate Inc |
Reactivos y conjugados de transporte de guanidinio.
|
|
US20030113349A1
(en)
*
|
2001-12-18 |
2003-06-19 |
Coleman William P. |
Topically applied clostridium botulinum toxin compositions and treatment methods
|
|
US7364586B2
(en)
*
|
2001-12-21 |
2008-04-29 |
The Trustees Of Columbia University In The City Of New York |
C3 exoenzyme-coated stents and uses thereof for treating and preventing restenosis
|
|
US20030147958A1
(en)
*
|
2002-01-29 |
2003-08-07 |
Cheol-Hee Ahn |
Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents
|
|
US20050163832A1
(en)
*
|
2002-02-13 |
2005-07-28 |
Vladimir Torchilin |
Intracellular delivery of therapeutic agents
|
|
WO2003072049A2
(en)
*
|
2002-02-21 |
2003-09-04 |
Essentia Biosystems, Inc. |
Induction of hair growth with vascular endothelial growth factor
|
|
WO2003102166A2
(en)
*
|
2002-02-26 |
2003-12-11 |
Maxygen, Inc. |
Novel flavivirus antigens
|
|
ATE494010T1
(de)
|
2002-02-27 |
2011-01-15 |
Pharmain Corp |
Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
|
|
US6688311B2
(en)
*
|
2002-03-14 |
2004-02-10 |
Allergan, Inc. |
Method for determining effect of a clostridial toxin upon a muscle
|
|
US20030215395A1
(en)
*
|
2002-05-14 |
2003-11-20 |
Lei Yu |
Controllably degradable polymeric biomolecule or drug carrier and method of synthesizing said carrier
|
|
US7459164B2
(en)
*
|
2002-05-28 |
2008-12-02 |
Botulinum Toxin Research Associates, Inc. |
Composition for therapeutic and cosmetic botulinum toxin
|
|
AU2003237346A1
(en)
*
|
2002-05-31 |
2003-12-19 |
Thomas Jefferson University |
Compositions and methods for transepithelial molecular transport
|
|
US20040009180A1
(en)
*
|
2002-07-11 |
2004-01-15 |
Allergan, Inc. |
Transdermal botulinum toxin compositions
|
|
US20040242518A1
(en)
|
2002-09-28 |
2004-12-02 |
Massachusetts Institute Of Technology |
Influenza therapeutic
|
|
US7071167B2
(en)
*
|
2002-11-13 |
2006-07-04 |
L'oreal |
Use of a combination of components with an inhibitory synergistic effect on calcium channels to prevent or treat wrinkles and fine lines
|
|
US6866856B2
(en)
*
|
2002-12-31 |
2005-03-15 |
Avon Products, Inc. |
Compositions and delivery methods for the treatment of wrinkles, fine lines and hyperhidrosis
|
|
US7482016B2
(en)
*
|
2003-03-19 |
2009-01-27 |
The J. David Gladstone Institutes |
Immunogenic compositions comprising HIV-1 acetylated Tat polypeptides
|
|
WO2004084839A2
(en)
*
|
2003-03-24 |
2004-10-07 |
Cady Roger K |
Method and article for treatment of sensory neuron related disorders through transdermal application of botulinum toxin
|
|
US20040192754A1
(en)
*
|
2003-03-24 |
2004-09-30 |
Shapira Nathan Andrew |
Methods for treating idiopathic hyperhidrosis and associated conditions
|
|
WO2005030119A2
(en)
*
|
2003-04-11 |
2005-04-07 |
Allergan, Inc. |
Botulinum toxin a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
|
|
WO2005007819A2
(en)
*
|
2003-07-09 |
2005-01-27 |
Wisconsin Alumni Research Foundation |
Charge-dynamic polymers and delivery of anionic compounds
|
|
DE10333317A1
(de)
|
2003-07-22 |
2005-02-17 |
Biotecon Therapeutics Gmbh |
Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA)
|
|
US8871224B2
(en)
|
2003-12-09 |
2014-10-28 |
Allergan, Inc. |
Botulinum toxin therapy for skin disorders
|
|
US9211248B2
(en)
|
2004-03-03 |
2015-12-15 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
PT1729821E
(pt)
|
2004-03-03 |
2013-10-23 |
Revance Therapeutics Inc |
Composições e métodos para aplicação tópica e administração transdérmica de toxinas botulínicas
|
|
AU2005251676B2
(en)
|
2004-03-03 |
2011-09-29 |
Revance Therapeutics, Inc. |
Compositions and methods for topical diagnostic and therapeutic transport
|
|
US7691381B2
(en)
|
2004-04-15 |
2010-04-06 |
Allergan, Inc. |
Stabilized biodegradable neurotoxin implants
|
|
US20060040882A1
(en)
*
|
2004-05-04 |
2006-02-23 |
Lishan Chen |
Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
|
|
GB2416122A
(en)
|
2004-07-12 |
2006-01-18 |
Ipsen Ltd |
Botulinum neurotoxin composition
|
|
BRPI0513850A
(pt)
*
|
2004-07-26 |
2008-05-20 |
Merz Pharma Gmbh & Co Kgaa |
composição terapêutica com uma neurotoxina botulìnica
|
|
US20060024331A1
(en)
*
|
2004-08-02 |
2006-02-02 |
Ester Fernandez-Salas |
Toxin compounds with enhanced membrane translocation characteristics
|
|
JP2006067889A
(ja)
*
|
2004-09-01 |
2006-03-16 |
Japan Science & Technology Agency |
Ｐｅｏと二本鎖核酸のコンジュゲート
|
|
EP1661912A1
(en)
|
2004-11-29 |
2006-05-31 |
Xigen S.A. |
Fusion protein comprising a BH3-domain of a BH3-only protein
|
|
US8022179B2
(en)
|
2005-03-03 |
2011-09-20 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of an oligopeptide
|
|
BRPI0608249A2
(pt)
|
2005-03-03 |
2009-12-08 |
Revance Therapeutics Inc |
formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica
|
|
JP2008532522A
(ja)
*
|
2005-03-08 |
2008-08-21 |
モレキュラー プローブス， インコーポレイテッド |
ナノ構造を用いた細胞膜電位差のモニターおよび操作
|
|
JP5356807B2
(ja)
*
|
2005-05-11 |
2013-12-04 |
アイトヘネーシシェ テフニーシェ ホフシューレ チューリッヒ |
原核細胞由来の組み換えｎ−グリコシル化タンパク質
|
|
US8168206B1
(en)
*
|
2005-10-06 |
2012-05-01 |
Allergan, Inc. |
Animal protein-free pharmaceutical compositions
|
|
US8137677B2
(en)
*
|
2005-10-06 |
2012-03-20 |
Allergan, Inc. |
Non-protein stabilized clostridial toxin pharmaceutical compositions
|
|
WO2007059528A2
(en)
|
2005-11-17 |
2007-05-24 |
Revance Therapeutics, Inc. |
Compositions and methods of topical application and transdermal delivery of botulinum toxins with reduced non-toxin proteins
|
|
US20100021502A1
(en)
*
|
2006-12-28 |
2010-01-28 |
Waugh Jacob M |
Compositions and Methods of Topical Application and Transdermal Delivery of Botulinum Toxins Stabililzed with Polypeptide Fragments Derived from HIV-TAT
|
|
CN102988995A
(zh)
|
2006-12-29 |
2013-03-27 |
雷文斯治疗公司 |
用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法
|
|
BRPI0720729A2
(pt)
*
|
2006-12-29 |
2014-04-08 |
Revance Therapeutics Inc |
Moléculas de transporte que utilizam polipeptídeos hiv-tat de sequência inversa.
|
|
HRP20181259T1
(hr)
*
|
2008-02-20 |
2018-10-05 |
Glaxosmithkline Biologicals S.A. |
Biokonjugati načinjeni iz rekombinantnih n-glikoziliranih proteina iz prokariotskih stanica
|
|
US20100028385A1
(en)
*
|
2008-08-04 |
2010-02-04 |
Allergan, Inc. |
Treatment of excess cerumen secretion
|
|
RU2011125776A
(ru)
*
|
2008-12-31 |
2013-02-10 |
Реванс Терапьютикс, Инк. |
Композиции и способы лечения гиперпигментации
|
|
HRP20180739T1
(hr)
*
|
2008-12-31 |
2018-06-29 |
Revance Therapeutics, Inc. |
Injekcijske formulacije botulinskog toksina
|
|
WO2010114828A1
(en)
*
|
2009-04-01 |
2010-10-07 |
Revance Therapeutics, Inc. |
Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
|
|
CA2766521C
(en)
|
2009-06-25 |
2020-07-21 |
Revance Therapeutics, Inc. |
Albumin-free botulinum toxin formulations
|
|
US8697090B2
(en)
|
2011-05-05 |
2014-04-15 |
Allergan, Inc. |
Method of treating persistent genital arousal disorder with a neurotoxin
|
|
US8586020B2
(en)
|
2011-06-30 |
2013-11-19 |
Korea Institute Of Science And Technology |
Poly(organophosphazene) composition for biomaterials
|
|
CA2848740A1
(en)
*
|
2011-09-16 |
2013-03-21 |
Mingxing Wang |
Amphiphilic cationic polymers for the delivery of therapeutic agents
|
|
KR20140102759A
(ko)
*
|
2011-12-16 |
2014-08-22 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
|
|
US9541558B2
(en)
*
|
2012-09-05 |
2017-01-10 |
California Institute Of Technology |
Cysteine hydrazide nicotinamide for glycomics and glycoproteomics uses
|
|
MX370929B
(es)
*
|
2012-10-28 |
2020-01-08 |
Revance Therapeutics Inc |
Composiciones y usos de las mismas para el tratamiento seguro de la rinitis.
|